A phase 1 safety and pharmacokinetic (PK) study of the PI3K inhibitor XL147 (SAR245408) in combination with erlotinib in patients with advanced solid tumors

被引：5
|
作者：
Faulkner, Neil
LoRusso, Patricia M.
Guthrie, Tina
Soria, Jean-Charles
Bahleda, Ratislav
Bendell, Johanna C.
Infante, Jeffrey R.
Massard, Christophe
Van Leeuwen, Barbara
Martini, Jean-Francois
Scheffold, Christian
Burns, Howard A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2009年 / 8卷 / 12期
关键词：
D O I：
10.1158/1535-7163,TARG-09-C197
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
C197
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A Phase I study of intravenous PI3K inhibitor copanlisib in Japanese patients with advanced or refractory solid tumors
    Doi, Toshihiko
    Fuse, Nozomu
    Yoshino, Takayuki
    Kojima, Takashi
    Bando, Hideaki
    Miyamoto, Hideaki
    Kaneko, Masato
    Osada, Motonobu
    Ohtsu, Atsushi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 89 - 98
  • [32] A Phase 1/2a Study of a PI3Kδγ. dual inhibitor ZX-101A in patients with advanced solid tumors
    Qin, Xiaoli
    Luo, Lori
    Li, Ying-ying
    Wang, Yin
    Sun, Shuaijun
    Hao, Xiaolin
    Yang, Jinfu
    CANCER RESEARCH, 2022, 82 (12)
  • [33] Phase I Trial of SAR245408 (S08), a Pan-Phosphatidylinositol 3 Kinase (PI3K) Inhibitor, in Patients with Chronic Lymphocytic Leukemia (CLL) and Lymphoma
    Brown, Jennifer R.
    Davids, Matthew S.
    Rodon, Jordi
    Abrisqueta, Pau
    DeCillis, Arthur P.
    Rockich, Kevin
    Egile, Coumaran
    Kelly, Adrianne
    Xu, Yi
    Lager, Joanne
    Awan, Farrukh T.
    BLOOD, 2011, 118 (21) : 1153 - 1153
  • [34] A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors
    LoRusso, P.
    Markman, B.
    Tabernero, J.
    Shazer, R.
    Nguyen, L.
    Heath, E.
    Patnaik, A.
    Papadopoulos, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [35] A Phase 1 safety and pharmacokinetic study of XL765 (SAR245409), a novel PI3K/TORC1/TORC2 inhibitor, in combination with temozolomide (TMZ) in patients (pts) with malignant glioma
    Wen, Patrick V.
    Omuro, Antonio M.
    Batchelor, Tracy T.
    Lai, Albert
    Mellinghoff, Ingo K.
    Nghiemphu, Leia
    Norden, Andrew
    Gendreau, Steven B.
    Laird, A. Douglas
    Nguyen, Linh
    Cloughesy, Timothy
    MOLECULAR CANCER THERAPEUTICS, 2009, 8 (12)
  • [36] Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
    Juric, Dejan
    Krop, Ian
    Ramanathan, Ramesh K.
    Wilson, Timothy R.
    Ware, Joseph A.
    Bohorquez, Sandra M. Sanabria
    Savage, Heidi M.
    Sampath, Deepak
    Salphati, Laurent
    Lin, Ray S.
    Jin, Huan
    Parmar, Hema
    Hsu, Jerry Y.
    Von Hoff, Daniel D.
    Baselga, Jose
    CANCER DISCOVERY, 2017, 7 (07) : 704 - 715
  • [37] First-in-Human Trial of the PI3Kβ-Selective Inhibitor SAR260301 in Patients With Advanced Solid Tumors
    Bedard, Philippe L.
    Davies, Michael A.
    Kopetz, Scott
    Juric, Dejan
    Shapiro, Geoffrey I.
    Luke, Jason J.
    Spreafico, Anna
    Wu, Bin
    Castell, Christelle
    Gomez, Corinne
    Cartot-Cotton, Sylvaine
    Mazuir, Florent
    Dubar, Michel
    Micallef, Sandrine
    Demers, Brigitte
    Flaherty, Keith T.
    CANCER, 2018, 124 (02) : 315 - 324
  • [38] A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors
    Omlin, Aurelius Gabriel
    Spicer, James F.
    Sarker, Debashis
    Pinato, David James
    Agarwal, Roshan
    Cassier, Philippe Alexandre
    Stavraka, Chara
    Blanco, Monsterrat
    Suder, Aneta
    Allan, Suzanne
    Heaton, Simon
    Decordova, Shaun
    Pope, Lorna
    Prince, Jenny
    Noguchi, Kohei
    Jones, Keith
    Inatani, Michiyasu
    Shiokawa, Rie
    Banerji, Udai
    Blagden, Sarah Patricia
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [39] A phase I pharmacokinetic and pharmacodynamic evaluation of the combination of everolimus and buparlisib for concurrent mTOR and PI3K pathway blockade in patients with advanced solid tumors
    Owonikoko, Taofeek Kunle
    Harvey, R. Donald
    Lewis, Colleen
    Chen, Zhengjia
    Kauh, John S.
    Renfroe, Meredith
    Deovic, Rijalda
    Sica, Gabriel L.
    Carthon, Bradley C.
    Harris, Wayne Bernard
    El-Rayes, Bassel F.
    Ramalingam, Suresh S.
    Khuri, Fadlo R.
    CANCER RESEARCH, 2015, 75
  • [40] A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors
    J. E. Grilley-Olson
    P. L. Bedard
    A. Fasolo
    M. Cornfeld
    L. Cartee
    A. R. Abdul Razak
    L.-A. Stayner
    Y. Wu
    R. Greenwood
    R. Singh
    C. B. Lee
    J. Bendell
    H. A. Burris
    G. Del Conte
    C. Sessa
    J. R. Infante
    Investigational New Drugs, 2016, 34 : 740 - 749
12345